--- title: "Analyst Expectations For Dianthus Therapeutics's Future" description: "Analysts have recently provided varied ratings for Dianthus Therapeutics (NASDAQ:DNTH), with an average 12-month price target of $62.25, reflecting a 15.28% increase from the previous target. Key anal" type: "news" locale: "en" url: "https://longbridge.com/en/news/256588938.md" published_at: "2025-09-09T14:01:07.000Z" --- # Analyst Expectations For Dianthus Therapeutics's Future > Analysts have recently provided varied ratings for Dianthus Therapeutics (NASDAQ:DNTH), with an average 12-month price target of $62.25, reflecting a 15.28% increase from the previous target. Key analysts have raised their ratings, with Guggenheim setting a target of $100.00. Despite these positive outlooks, the company faces significant revenue challenges, with a decline of approximately -89.64% over the past three months and a net margin of -16388.08%. Dianthus Therapeutics is focused on developing novel monoclonal antibodies for severe autoimmune diseases. In the preceding three months, 4 analysts have released ratings for Dianthus Therapeutics (NASDAQ:DNTH), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. **Bullish** **Somewhat Bullish** **Indifferent** **Somewhat Bearish** **Bearish** **Total Ratings** 2 2 0 0 0 **Last 30D** 1 1 0 0 0 **1M Ago** 1 1 0 0 0 **2M Ago** 0 0 0 0 0 **3M Ago** 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Dianthus Therapeutics, presenting an average target of $62.25, a high estimate of $100.00, and a low estimate of $40.00. This current average has increased by 15.28% from the previous average price target of $54.00. ![price target chart](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1757426464_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) ## Interpreting Analyst Ratings: A Closer Look In examining recent analyst actions, we gain insights into how financial experts perceive Dianthus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yatin Suneja Guggenheim Raises Buy $100.00 $92.00 Joel Beatty Baird Raises Outperform $67.00 $50.00 Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $40.00 $40.00 Laura Chico Wedbush Raises Outperform $42.00 $34.00 ### Key Insights: - **Action Taken:** Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company. - **Rating:** Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dianthus Therapeutics compared to the broader market. - **Price Targets:** Gaining insights, analysts provide estimates for the future value of Dianthus Therapeutics's stock. This comparison reveals trends in analysts' expectations over time. To gain a panoramic view of Dianthus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table. Stay up to date on Dianthus Therapeutics analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here. ## About Dianthus Therapeutics Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. ### Key Indicators: Dianthus Therapeutics's Financial Health **Market Capitalization Analysis:** The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers. **Revenue Challenges:** Dianthus Therapeutics's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately **\-89.64%**. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector. **Net Margin:** Dianthus Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of **\-16388.08%,** the company may face hurdles in effective cost management. **Return on Equity (ROE):** Dianthus Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of **\-10.01%,** the company may face hurdles in generating optimal returns for shareholders. **Return on Assets (ROA):** Dianthus Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of **\-9.38%,** the company may encounter challenges in delivering satisfactory returns from its assets. **Debt Management:** Dianthus Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of **0.0**, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. ## The Basics of Analyst Ratings Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors. **Breaking: Wall Street's Next Big Mover** Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details. This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [DNTH.US - Dianthus Therapeutics](https://longbridge.com/en/quote/DNTH.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 4 位分析師對 Dianthus Therapeutics 的評級意見 | 在最新的季度中，4 位分析師對 Dianthus Therapeutics（NASDAQ:DNTH）進行了評級，顯示出看漲和看跌情緒的混合。12 個月的平均目標價為 61.25 美元，比之前的目標價 53.50 美元上漲了 14.49%。分 | [Link](https://longbridge.com/en/news/275656538.md) | | Hacker Interstellar 申請在美國進行首次公開募股（IPO） | 黑客跨星際文件用於美國 IPO - SEC 備案 | [Link](https://longbridge.com/en/news/275901818.md) | | 威斯康星大學麥迪遜分校要求學生報告麻疹疫苗接種情況 | 威斯康星大學麥迪遜分校已要求學生披露其麻疹、腮腺炎和風疹等疾病的疫苗接種狀態，此舉是在校園內出現近期麻疹病例後實施的。該政策旨在增強公共健康意識，併為高風險學生提供更好的支持。此公告是在全國麻疹病例增加的背景下發布的，衞生官員呼籲進行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) | | Medikra 現在預計在美國進行 4.5 百萬普通股的首次公開募股 | Medikra Inc：MEDIKRA INC - 為納斯達克上市保留符號 “MDKR” - SEC 備案 Medikra Inc：現在預計美國首次公開募股（IPO）將發行最多 450 萬股普通股 - SEC 備案 | [Link](https://longbridge.com/en/news/275943061.md) | | 簡訊——據彭博新聞報道，數字銀行 Maya 正在考慮在美國進行規模高達 10 億美元的首次公開募股 | 2 月 16 日（路透社）- * 據彭博社報道，數字銀行 Maya 正在考慮進行高達 10 億美元的美國首次公開募股（IPO）- 來源文本：進一步的公司報道：[ ] | [Link](https://longbridge.com/en/news/276039136.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.